Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Texas Oncology PA
mi
from
McAllen, TX
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Texas Oncology PA
mi
from
McAllen, TX
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Cancer Therapy & Research Center / UT Health Science Center Oncology Dept.
mi
from
San Antonio, TX
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Cancer Therapy & Research Center / UT Health Science Center Oncology Dept.
mi
from
San Antonio, TX
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Deke Slayton Cancer Center Deke Slayton Cancer Center (2)
mi
from
Webster, TX
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Deke Slayton Cancer Center Deke Slayton Cancer Center (2)
mi
from
Webster, TX
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Intermountain Medical Center Intermountain Healthcare
mi
from
Murray, UT
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Intermountain Medical Center Intermountain Healthcare
mi
from
Murray, UT
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Northern Utah Cancer Associates Northern Utah Assoc (3)
mi
from
Ogden, UT
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Northern Utah Cancer Associates Northern Utah Assoc (3)
mi
from
Ogden, UT
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
University of Utah / Huntsman Cancer Institute SC-2
mi
from
Salt Lake City, UT
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
University of Utah / Huntsman Cancer Institute SC-2
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Utah Cancer Specialists Utah Cancer Specialists (11)
mi
from
Salt Lake City, UT
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Utah Cancer Specialists Utah Cancer Specialists (11)
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Virginia Cancer Specialists, PC Fairfax Northern Virginia
mi
from
Fairfax, VA
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Virginia Cancer Specialists, PC Fairfax Northern Virginia
mi
from
Fairfax, VA
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Shenandoah Oncology Shenandoah Oncology (5)
mi
from
Winchester, VA
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Shenandoah Oncology Shenandoah Oncology (5)
mi
from
Winchester, VA
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Northwest Medical Specialties NW Medical Specialties
mi
from
Tacoma, WA
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Northwest Medical Specialties NW Medical Specialties
mi
from
Tacoma, WA
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
San Francisco General Hospital San Francisco Gen Hosp (7)
mi
from
San Francisco, CA
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
San Francisco General Hospital San Francisco Gen Hosp (7)
mi
from
San Francisco, CA
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Norwalk Hospital
mi
from
Norwalk, CT
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Norwalk Hospital
mi
from
Norwalk, CT
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists Florida Cancer Specialists 36
mi
from
Fort Myers, FL
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists Florida Cancer Specialists 36
mi
from
Fort Myers, FL
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
University of Miami Sylvester Comprehensive Cancer
mi
from
Miami, FL
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
University of Miami Sylvester Comprehensive Cancer
mi
from
Miami, FL
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Community Clinical Research Center
mi
from
Anderson, IN
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Community Clinical Research Center
mi
from
Anderson, IN
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Minnesota Oncology Hematology, P.A. Minnesota Oncology Hem (27)
mi
from
Minneapolis, MN
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology Hematology, P.A. Minnesota Oncology Hem (27)
mi
from
Minneapolis, MN
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Health Hem & Onc Medical Center
mi
from
Winston-Salem, NC
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Health Hem & Onc Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Sanford University of South Dakota Medical Center Sanford Health
mi
from
Sioux Falls, SD
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Sanford University of South Dakota Medical Center Sanford Health
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology
mi
from
Chattanooga, TN
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology
mi
from
Chattanooga, TN
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Cancer Care & Research Center Texas Oncology
mi
from
Waco, TX
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Cancer Care & Research Center Texas Oncology
mi
from
Waco, TX
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Billings Clinic Billings Clinic (8)
mi
from
Billings Montana, MT
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Billings Clinic Billings Clinic (8)
mi
from
Billings Montana, MT
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
Cancer Treatment Centers of America Eastern Regional Medical Center
mi
from
Philadelphia, PA
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
Cancer Treatment Centers of America Eastern Regional Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
University of N C at Chapel Hill Physician Office Building
mi
from
Chapel Hill, NC
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
University of N C at Chapel Hill Physician Office Building
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine and Rituximab, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine and Rituximab, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed By Maintenance Therapy With the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-risk Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
Northside Hospital
mi
from
Atlanta, GA
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed By Maintenance Therapy With the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-risk Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
Northside Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Prospective Observation of Cardiac Safety With Proteasome Inhibition
Prospective Observation of Cardiac Safety With Proteasome Inhibition
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Prospective Observation of Cardiac Safety With Proteasome Inhibition
Prospective Observation of Cardiac Safety With Proteasome Inhibition
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Prospective Observation of Cardiac Safety With Proteasome Inhibition
Prospective Observation of Cardiac Safety With Proteasome Inhibition
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania/Smilow Center for Translational Research
mi
from
Philadelphia, PA
Prospective Observation of Cardiac Safety With Proteasome Inhibition
Prospective Observation of Cardiac Safety With Proteasome Inhibition
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania/Smilow Center for Translational Research
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
A Phase I Study Evaluating the Efficacy and Safety of Sodium Selenite in Combination With Palliative Radiation Therapy in Patients With Metastatic Cancer
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
A Phase I Study Evaluating the Efficacy and Safety of Sodium Selenite in Combination With Palliative Radiation Therapy in Patients With Metastatic Cancer
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
A Phase 1b Multi-Center, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Anti-Tumor Activity of an Alternative Liquid Formulation of ACY-1215 (Ricolinostat) In Combination With Pomalidomide and Low-Dose Dexamethasone In Patients With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
UT Southwestern Medical Center / Simmons Comprehensive Cancer Center
mi
from
Dallas, TX
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
A Phase 1b Multi-Center, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Anti-Tumor Activity of an Alternative Liquid Formulation of ACY-1215 (Ricolinostat) In Combination With Pomalidomide and Low-Dose Dexamethasone In Patients With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
UT Southwestern Medical Center / Simmons Comprehensive Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
A Phase 1b Multi-Center, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Anti-Tumor Activity of an Alternative Liquid Formulation of ACY-1215 (Ricolinostat) In Combination With Pomalidomide and Low-Dose Dexamethasone In Patients With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
CTRC at The UT Health Science Center at San Antonio
mi
from
San Antonio, TX
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
A Phase 1b Multi-Center, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Anti-Tumor Activity of an Alternative Liquid Formulation of ACY-1215 (Ricolinostat) In Combination With Pomalidomide and Low-Dose Dexamethasone In Patients With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
CTRC at The UT Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
A Phase 1b Multi-Center, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Anti-Tumor Activity of an Alternative Liquid Formulation of ACY-1215 (Ricolinostat) In Combination With Pomalidomide and Low-Dose Dexamethasone In Patients With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
University of Utah, Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
A Phase 1b Multi-Center, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Anti-Tumor Activity of an Alternative Liquid Formulation of ACY-1215 (Ricolinostat) In Combination With Pomalidomide and Low-Dose Dexamethasone In Patients With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
University of Utah, Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors
Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14)
Status: Enrolling
Updated:  12/31/1969
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors
Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14)
Status: Enrolling
Updated: 12/31/1969
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors
Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14)
Status: Enrolling
Updated:  12/31/1969
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors
Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14)
Status: Enrolling
Updated: 12/31/1969
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors
Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14)
Status: Enrolling
Updated:  12/31/1969
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors
Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14)
Status: Enrolling
Updated: 12/31/1969
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors
Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14)
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors
Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14)
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors
Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14)
Status: Enrolling
Updated:  12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors
Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14)
Status: Enrolling
Updated: 12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors
Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14)
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors
Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14)
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)
Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)
Status: Enrolling
Updated:  12/31/1969
UAB Medical Center (University of Alabama at Birmingham)
mi
from
Birmingham, AL
Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)
Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)
Status: Enrolling
Updated: 12/31/1969
UAB Medical Center (University of Alabama at Birmingham)
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
A Phase 1/2a, Dose Escalation Study of FF-10501-01 for the Treatment of Advanced Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
A Phase 1/2a, Dose Escalation Study of FF-10501-01 for the Treatment of Advanced Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
A Phase 1/2a, Dose Escalation Study of FF-10501-01 for the Treatment of Advanced Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
A Phase 1/2a, Dose Escalation Study of FF-10501-01 for the Treatment of Advanced Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation
Phase II Study of Sorafenib Plus 5-Azacitidine for the Initial Therapy of Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome With FLT3-ITD Mutation
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation
Phase II Study of Sorafenib Plus 5-Azacitidine for the Initial Therapy of Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome With FLT3-ITD Mutation
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic - Scottsdale /ID# 129701
mi
from
Scottsdale, AZ
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic - Scottsdale /ID# 129701
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy
Status: Enrolling
Updated:  12/31/1969
City of Hope /ID# 129718
mi
from
Duarte, CA
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy
Status: Enrolling
Updated: 12/31/1969
City of Hope /ID# 129718
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy
Status: Enrolling
Updated:  12/31/1969
UC Davis Comp Cancer Ctr /ID# 129719
mi
from
Sacramento, CA
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy
Status: Enrolling
Updated: 12/31/1969
UC Davis Comp Cancer Ctr /ID# 129719
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy
Status: Enrolling
Updated:  12/31/1969
University of Colorado Cancer Center /ID# 127859
mi
from
Aurora, CO
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy
Status: Enrolling
Updated: 12/31/1969
University of Colorado Cancer Center /ID# 127859
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy
Status: Enrolling
Updated:  12/31/1969
Emory University Hospital /ID# 129715
mi
from
Atlanta, GA
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy
Status: Enrolling
Updated: 12/31/1969
Emory University Hospital /ID# 129715
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy
Status: Enrolling
Updated:  12/31/1969
Northwestern University /ID# 128741
mi
from
Chicago, IL
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy
Status: Enrolling
Updated: 12/31/1969
Northwestern University /ID# 128741
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy
Status: Enrolling
Updated:  12/31/1969
University of Chicago /ID# 128742
mi
from
Chicago, IL
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy
Status: Enrolling
Updated: 12/31/1969
University of Chicago /ID# 128742
mi
from
Chicago, IL
Click here to add this to my saved trials